bis-(2-chloroethyl)(2-phenylethyl)amine hydrochloride | 100249-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis-(2-chloroethyl)(2-phenylethyl)amine hydrochloride
• 英文别名: bis-(2-chloro-ethyl)-phenethyl-amine; hydrochloride；Bis-(2-chlor-aethyl)-phenaethyl-amin; Hydrochlorid；N-(2-phenylethyl)-N,N-bis(2-chloroethyl)amine hydrochloride；N,N-Bis(2-chloroethyl)-2-phenylethylamine hydrochloride；N,N-bis(2-chloroethyl)-2-phenylethanamine;hydrochloride
• CAS: 100249-12-5
• 化学式: C₁₂H₁₇Cl₂N*ClH
• 分子量: 282.641
• InChiKey: KMOSAHPINLATIL-UHFFFAOYSA-N

物化性质

• 熔点：
  110-111 °C(Solv: benzene (71-43-2); chloroform (67-66-3))

计算性质

• 辛醇/水分配系数(LogP)：
  3.43
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  bis-(2-chloroethyl)(2-phenylethyl)amine hydrochloride 在 sodium hydroxide 、 草酰氯 、 18-冠醚-6 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 89.0h， 生成
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationship of N-Substituted 4-Arylsulfonylpiperidine-4-hydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis

  摘要：

  The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue degradation. In our preceding paper, we have reported on a series of novel and orally active N-hydroxy-alpha-phenylsulfonylacetamide derivatives. However, these compounds had two drawbacks (moderate selectivity and chirality issues). To circumvent these two problems, a series of novel and orally active N-substituted 4-benzenesulfonylpiperidine-4-carboxylic acid hydroxyamide derivatives have been synthesized. The present paper deals with the synthesis and SAR of these compounds. Among the several compounds synthesized, derivative 55 turned out to be a potent, selective, and an orally active MMP inhibitor in the clinically relevant advanced rabbit osteoarthritis model. Detailed pharmacokinetics and metabolism data are described.

  DOI：

  10.1021/jm0205550
• 作为产物：
  描述：

  2-[2-羟基乙基(2-苯基乙基)氨基]乙醇 在 氯化亚砜 作用下， 生成 bis-(2-chloroethyl)(2-phenylethyl)amine hydrochloride
  参考文献：
  名称：

  Photoactive chemosensors 3 : a unique case of fluorescence enhancement with Cu(ii)

  摘要：

  化学传感器（4a）在使用 Cu（II）时荧光增强，利用荧光（1-20 μM）和紫外可见光（10-300 μM）光谱技术可估算出 1-300 μM 的 Cu（II）。镍（II）、镉（II）、锌（II）、银（I）和汞（II）不干扰荧光研究，只有银（I）和汞（II）干扰紫外可见光研究。

  DOI：

  10.1039/b209053h

文献信息

• 1,4-(diphenlyalkyl) piperazine derivatives
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US05736546A1

  公开（公告）日：1998-04-07

  This invention relates to novel compounds of the formula \x9bI!, ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents a lower alkoxy group; A and B are the same or different and each represents a lower alkylene group. The compounds of this invention have affinities for sigma receptors and are useful for therapeutic agents for cerebral neural function disorders such as dementia, depression, schizophrenia and anxiety neurosis, diseases accompanying abnormal immune response and cryptorrhea, digestive ulcer, etc.

  本发明涉及通式Ⅰ的新颖化合物， ##STR1## 其中R1和R2相同或不同，各自代表低级烷氧基团；A和B相同或不同，各自代表低级亚烷基团。本发明的化合物对σ受体具有亲和力，可作为治疗脑神经功能障碍如痴呆、抑郁、精神分裂症和焦虑神经症、伴随异常免疫反应的疾病以及遗尿症、消化性溃疡等的药物。
• (N-phthalimidoalkyl)piperidines
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05480892A1

  公开（公告）日：1996-01-02

  There are described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.

  描述了一种新型(N-邻苯二甲酰亚烷基)哌啶化合物，其表现出选择性的σ受体拮抗作用，因此可用于治疗哺乳动物中的生理或药物诱导的精神病和运动障碍。还描述了含有σ选择性化合物的药物组合物以及使用这些组合物治疗哺乳动物中的生理或药物诱导的精神病或运动障碍的方法。此外，还提供了制备本发明化合物的方法。
• (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05356906A1

  公开（公告）日：1994-10-18

  There is described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.

  本文描述了一种新型的（N-邻苯二甲酰亚烷基）哌啶化合物，其表现出选择性的sigma受体拮抗作用，因此可用于治疗哺乳动物的生理或药物诱导的精神病和运动障碍。还描述了含有sigma选择性化合物的制药组合物以及使用这些组合物治疗哺乳动物的生理或药物诱导的精神病或运动障碍的方法。此外，还提供了制备本发明化合物的方法。
• NOVEL 1,4-DI(PHENYLALKYL)PIPERAZINE DERIVATIVE
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP0711763A1

  公开（公告）日：1996-05-15

  A novel compound represented by general formula [I], wherein R¹ and R² may be the same or different from each other and each represents lower alkoxy; and A and B may be the same or different from each other and each represents lower alkylene. It has a σ receptor affinity and is useful as a remedy for diseases accompanying cranial nerve function disorder, such as dementia, depression, schizophrenia and anxiety, immunopathy and cryptorrhea, and digestive ulcer.

  一种由通式[I]代表的新型化合物，其中R¹和R²可以彼此相同或不同，并且各自代表低级烷氧基；A和B可以彼此相同或不同，并且各自代表低级亚烷基。它具有σ受体亲和力，可用于治疗伴随颅神经功能紊乱的疾病，如痴呆、抑郁、精神分裂症和焦虑症、免疫病和隐性感染以及消化道溃疡。
• (N-PHTHALIMIDOALKYL) PIPERIDINES
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0497843A1

  公开（公告）日：1992-08-12